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bHonorary Editor, Indian Heart JournalFig. 1 e KaplaneMeier estimates of the probability of death
from coronary heart disease in 1059 subjects6 [reproduced
with permission].The recent publication of the results of “FREEDOM” trial has
cast considerable doubt in the minds of physicians about the
utility of multi-vessel angioplasty even while using drug
eluting stents.1 We need to examine the results of this land-
mark trial in detail in addition to the earlier data available on
PCI among diabetics before incorporating the results of the
FREEDOM trial into our daily practice.
According to the Diabetes Atlas 2006 published by the
International Diabetes Federation, the number of people with
diabetes in India which is currently around 40.9 million is
expected to rise to 69.9 million by 2025.2 A national survey of
diabetes conducted in six major cities in India in the year 2000
showed that the prevalence of diabetes in urban adults was
12.1%. Prevalence of impaired glucose tolerance (IGT) was also
high at 14.0%.3 With this high degree prevalence, it is under-
standable that 30e40% of patients in India who come for PCI
are diabetics.4 Therefore, the results of FREEDOM trial are of
particular relevance to us.
The National Cholesterol Education Program report from
the United States and guidelines from Europe consider type 2
diabetes to be a CHD equivalent, thereby elevating it to the
highest risk category.5 This classification was based in part
upon the observation that patients with type 2 diabetes
without a prior MI (mean age 58) were at the same risk for MI
(20 versus 19 percent) and coronary mortality (15 versus 16
percent) as patients without diabetes who had a prior MI
(mean age 56) [Fig. 1].6
Historically patients with diabetes who undergo PCI have
been a difficult-to-treat patient population. They tend to have
smaller and often tortuous arteries, longer lesions, diffused
disease and a higher rate of treatment failures including rel-
atively high rates of repeat procedures and stent thrombosis.7* Corresponding author.
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http://dx.doi.org/10.1016/j.ihj.2013.01.002The FREEDOM trial was sponsored by the National Heart,
Lung, and Blood Institute, USA. It was a well planned and
executed study with 1900 patients of DM (Type I & Type II)
randomized to PCI or CABG. The inclusion criteria were that
they had two or three vessel disease with at least one 70%
lesion in the vessel treated. Patients with LMCA disease were
excluded. About 32% of patients were on insulin in both the
groups. The HbA1c at the outset was around 7.8% in both the
groups. Majority of patients had three vessel diseases (82%).
About 70% were men and the average age was 63 years.1,8
First generation sirolimus-eluting and paclitaxel-eluting
stents were used exclusively in 51% and 43% of patients
respectively, in the PCI group. Number of lesions stented wasty of India. All rights reserved.
Fig. 2 e Definite and probable stent thrombosis rates at
1 year in the SPIRIT V registry.
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mended for a minimum period of 1 year to PCI group. The
mean SYNTAX score was 26.2  8.6 and mean Euro SCORE
2.75  2.45 which shows majority patients were of interme-
diate SYNTAX score. Surgery was off-pump in 18.5% of cases.
LIMA was used in 94% of patients.1,8
The primary composite endpoint whichwas a combination
of death from any cause,myocardial infarction and strokewas
significantly lower in the CABG-treated patients, as was the
five-year rate of all-causemortality andmyocardial infarction.
Following revascularization, the five-year rate of all-cause
mortality, myocardial infarction, and stroke was 26.6% in
the PCI-treated patients and 18.7% among patients who un-
derwent CABG surgery, a statistically significant relative risk
reduction of 30%. Stroke rates were significantly higher in the
CABG arm, mainly because of the excess of stroke in the first
30 days. Of the strokes, most (87%) were ischemic strokes and
13% were hemorrhagic. The results are shown in Table 1.
The trial despite excluding the need for repeat revascula-
rization from the primary composite endpoint clearly shows
that surgery is better in the long run for this group of patients.
There is a mortality benefit as well as continuing benefit in
terms of reduced risk ofmyocardial infarction among patients
who underwent CABG. Although stroke is more in the surgical
group, most cases of stroke occurred in the early post-
operative period.
Even the most diehard interventionist cannot escape the
conclusion that surgery proved better in the FREEDOM trial.
Importantly, surgery proved better in all subgroups including
different subsets of SYNTAX score.
There are some points to remember. Modern antiplatelet
agents like prasugrel or ticagrelor were not used in FREEDOM
trial. We are now aware that prasugrel has a particular
advantage for diabetics in that it reduces stent thrombosis.
Compared to the clopidogrel group in the TRITON TIMI 38
study, the prasugrel group had a 52% relative reduction for
stent thrombosis.9
With regard to ticagrelor, the pivotal PLATO trial has
shown that at 12 months, the primary endpointda composite
of death from vascular cause, myocardial infarction, or stro-
kedhad occurred in 9.8% of patients receiving ticagrelor asTable 1 e KaplaneMeier estimates of key outcomes at 2 year a
[reproduced with permission].1
Outcome 2 Years after randomization 5 Yea
PCI CABG P
Number (percen
Primary compositea 121 (13.0) 108 (11.9) 200
Death from any cause 62 (6.7) 57 (6.3) 114
Myocardial infarction 62 (6.7) 42 (4.7) 98
Stroke 14 (1.5) 24 (2.7) 20
Cardiovascular death 9 (0.9) 12 (1.3) 73
*P values were calculated with the use of the log-rank test on the basis o
zp ¼ 0.006 in the as-treated (non-intention-to-treat) analysis.
xp ¼ 0.16 by the Wald test of the Cox regression estimate for study-group
level after the procedure.
a The primary composite outcome was the rate of death from any causecompared with 11.7% in those receiving clopidogrel. Myo-
cardial infarction has also been shown to be reduced in the
ticagrelor arm (5.8% in the ticagrelor group vs. 6.9% in the
clopidogrel group, p ¼ 0.005).10
Thus the use of modern generation P2 Y12 inhibitors if
used in FREEDOM trial might have made a difference to the
outcomes.
In addition, we need to examine the outcomes of newer
generation drug eluting stents in diabetic patients. The
new Resolute Integrity Zotarolimus-eluting coronary stent
(Medtronic) has been approved by the Food and Drug
Administration (FDA) specifically for use in diabetics. It is the
first drug eluting stent approved by the FDA for use in patients
with diabetes. This was done on the basis of the results of the
RESOLUTE Global Clinical Program, which included a total of
five trials with identical inclusion and exclusion criteria [the
randomized RESOLUTE All Comers (R-AC, N ¼ 1140), plus
RESOLUTE First-in-Man (N ¼ 139), RESOLUTE US (N ¼ 1402),
RESOLUTE International (N ¼ 2349), and RESOLUTE Japan
(N ¼ 100)]. All 5 Resolute trials were designed with similar
endpoints and statistical methodologies, and all required the
same regimen of dual antiplatelet therapy. An ad hoc analysis
has pooled outcomes for the 5130 recipients of the Resolute
ZES in these 5 clinical trials.11nd 5 year after randomization in the FREEDOM trial
rs after randomization Patients with event p value*
CI CABG PCI CABG
t) Number
(26.6) 146 (18.7) 205 147 0.005z
(16.3) 83 (10.9) 118 86 0.049
(13.9) 48 (6.0) 99 48 <0.001
(2.4) 37 (5.2) 22 37 0.03x
(10.9) 52 (6.8) 75 55 0.12
f all available follow-up data (i.e., more than 5 years).
assignment in 1712 patients after adjustment for the average glucose
, myocardial infarction, or stroke.
Table 2 e Comparison of FREEDOM surgical arm with outcomes of Xience V trials and RESOLUTE All Comers trial.
Clinical endpoints FREEDOM trial [CABG arm] Meta-analysis of Xience V trials RESOLUTE All Comers trial
2 Years after
randomization
Clinical outcomes at 2 year data
in diabetic patients
Clinical outcomes at 2 year
Resolute Xience V
Primary composite outcome 11.9% 10.1% 12.5% 12.9%
Myocardial infarction 4.7% 4.2% 5.5% 5.0%
Cardiovascular death 1.3% 2.1% 2.6% 2.2%
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1 1 4e1 1 6116For the total population of DM patients, 2-year outcomes
were compared with those for 3595 non-DM patients from the
pooled cohort. Expectedly, rates of major adverse cardiac
events were significantly higher in DM patients than in
non-DM patients. However, the 2-year incidence of stent
thrombosis was very low regardless of the presence or
severity of diabetes (0.82% for non-DM patients, 0.93% for
non-insulin-treated DM patients, and 1.79% for insulin-
treated DM patients). When outcomes were analyzed by
treatment with insulin, the incidence of target lesion failure
was nearly the same for non-insulin-treated DM patients
versus non-DM patients but was significantly higher for
insulin-treated DM patients (8.4% for non-diabetics, 8.9% for
non-insulin-treated DM patients, and 16.7% for insulin-
treated DM patients).12
With respect to everolimus-eluting stente Xience (Abbott),
the SPIRIT V registry showed a low rate of death, myocardial
infarction, and TVR at 1 year (6.8%) in 2700 patients and the
outcomes of the DM subgroup (30% of the population) did not
significantly differ from the overall study results.13 The overall
one year cumulative stent thrombosis rate was 0.66% as
shown in Fig. 2.
We made an attempt to compare the 2 year results of
FREEDOM surgical arm with 2 year results of everolimus and
zotarolimus eluting stents as shown in Table 2. Although
these are different trials with different endpoints, one can
draw some idea from this table and it appears that the results
are reasonably comparable. Is it possible that if one of these
modern drug eluting stents were used in FREEDOM trial the
results could have been different?
One should also remember that even surgery is notwithout
its disadvantages among diabetics. In a review of 9920 pa-
tients with diabetes and 2278 patients without diabetes from
a single center over 15 years, Calafiore et al revealed lower
survival rates in diabetic patients versus non-diabetic patients
at five-year (78% versus 88%) and 10-year (50% versus 71%)
follow-up.14 Diabetes increases the risk of stroke, rates of
sternal wound infection, mediastinitis and saphenous vein
harvest site infections, renal failure, postoperativemyocardial
dysfunction leading to postoperative low cardiac output syn-
drome with CABG and valve surgery, leading to prolonged
postoperative intensive care unit stays. In the follow-up
period, they have increased risk for readmission. Thus we
need to understand that a diabetic has certain inherent dis-
advantages even while under going CABG.7
Conclusion: based on the data from FREEDOM trial, CABG
appears to be the treatment of choice for multi-vessel disease
in diabetics. However as antiplatelet therapy and especiallymodern drug eluting stents evolve, the difference in outcomes
between PCI and CABG could narrow down.r e f e r e n c e s
1. Farkouh ME, Domanski M, Sleeper L, et al. Strategies for
multivessel revascularization in patients with diabetes. N
Engl J Med. 2012;367:2375e2384.
2. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C.
Epidemiology of type 2 diabetes: Indian scenario. Indian J Med
Res. 2007;125:217e230.
3. Ramachandran A. Socio-economic burden of diabetes in
India. J Assoc Physicians India. 2007;55(suppl):9e12.
4. Panchal K, Patel S, Bhatt P. Drug-eluting stents in multivessel
coronary artery disease: cost Effectiveness and clinical
outcomes. Adv Pharm Sci; 2012:1e6 [cited 2013 Jan 4].
5. Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel). NIH Publication; 2002.
6. Haffner S, Lehto S. Mortality from coronary heart disease in
subjects with type 2 diabetes and in nondiabetic subjects with
and without prior myocardial infarction. N Engl J Med;
1998:229e234 [cited 2013 Jan 4].
7. Singh M, Arora R, Kodumuri V. Coronary revascularization in
diabetic patients: current state of evidence. Exp Clin Cardiol.
2011;16:16e22.
8. Bansilal S, Farkouh ME, Hueb W, et al. The Future
REvascularization Evaluation in patients with Diabetes
mellitus: optimal management of Multivessel disease
(FREEDOM) trial: clinical and angiographic profile at study
entry. Am Heart J. 2012;164:591e599.
9. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38
Investigators. Prasugrel versus clopidogrel in patients with
acute coronary syndromes. N Engl J Med. 2007;357:2001e2015.
10. Wallentin L, Becker R. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes. N Engl J Med
[Internet]. 2009;361:1045e1057 [cited 2013 Jan 7].
11. Belardi J. Pooled analysis of clinical events from prospective
trials of the Resolute zotarolimus-eluting stent: two year
outcomes of 5130 patients. In: Presented at the American College
of Cardiology, Chicago, March 24e27; 2012.
12. Yeung AC. The Resolute zotarolimus-eluting stent in patients
with diabetes mellitus: two year outcomes. In: Presented at the
American College of Cardiology, Chicago, March 24e27; 2012.
13. Grube E, Chevalier B, Smits P, et al. The SPIRIT V study:
a clinical evaluation of the XIENCE V everolimus-eluting
coronary stent system in the treatment of patients with de
novo coronary artery lesions. JACC Cardiovasc Interv.
2011;4:168e175.
14. Calafiore AM, Di Mauro M, Di Giammarco G, et al. Effect of
diabetes on early and late survival after isolated first coronary
bypass surgery in multivessel disease. J Thorac Cardiovasc
Surg. 2003;125:144e154.
